

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

**MATTOON & ASSOC, LLC.**

2. Address:

1001 G Street, NW Suite 750 East, Washington, DC 20001-4545

3. Principal place of business (if different from line 2):

4. Contact Name: REBECCA GOODING

Telephone: 2028799313

E-mail (optional): rgooding@mattoonassoc.com

Senate ID #: 314215-238

House ID #:

7. Client Name: ☐ Self

**PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA**

### TYPE OF REPORT

8. Year 2007 Midyear (January 1 - June 30): ☒ **OR** Year End (July 1 - December 31): ☐

9. Check if this filing amends a previously filed version of this report: ☐

10. Check if this is a Termination Report: ☐ => Termination Date: 11. No Lobbying Activity: ☐

### INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

#### 12. Lobbying Firms

**INCOME** relating to lobbying activities for this reporting period was:

Less than \$10,000: ☐

\$10,000 or more: ☒ => Income (nearest \$20,000): 180,000.00

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

#### 13. Organizations

**EXPENSES** relating to lobbying activities for this reporting period were:

Less than \$10,000: ☐

\$10,000 or more: ☐ => Expenses (nearest \$20,000): \_\_\_\_\_

#### 14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

- ☐ **Method A.** Reporting amounts using LDA definitions only  
☐ **Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code  
☐ **Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

Registrant Name: MATTOON & ASSOC, LLC. Client Name: PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA

**LOBBYING ACTIVITY**

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: BUD (one per page)

16. Specific lobbying issues:

HR 3161 and S 1859 FY08 Agriculture Appropriations bill - provisions related to FDA, drug importation HR 3043 and S 1710 FY08 LHHS Appropriations - provisions related to Medicare and drug pricing HR 2638 & S 1644 FY08 DHS Appropriations - provisions related to drug importation S 965 US. Troop Readiness, Veterans' Care, Katrina Recovery, and Iraq Accountability Appropriations Act, 2007 - provisions related to intergovernmental transfers H. Con Res 99 & S Con Res 21 Budget Resolutions - provisions related to drug importation and Medicare/Medicaid S 1745 & HR 3093 FY08 CJS Appropriations - provisions related to DEA drug importation

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: GOODING, REBECCA

Covered Official Position (if applicable): N/A

Name: MATTOON, DANIEL

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: MATTOON & ASSOC, LLC. Client Name: PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA

**LOBBYING ACTIVITY**

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: CPT (one per page)

16. Specific lobbying issues:

S 1145 and HR 1908 Patent Reform Act of 2007 - all provisions

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: GOODING, REBECCA

Covered Official Position (if applicable): N/A

Name: MATTOON, DANIEL

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above: **None**

Registrant Name: MATTOON & ASSOC, LLC. Client Name: PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA

**LOBBYING ACTIVITY**

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MMM (one per page)

16. Specific lobbying issues:

HR 4 & S 3 Medicare Prescription Drug Price Negotiation Act of 2007 - all provisions HR 3162 CHAMP Act - provisions related to Medicare cuts to finance package S 1893 Children's Health Insurance Program Reauthorization Act of 2007 - provisions related to Medicare cuts to finance package

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: GOODING, REBECCA

Covered Official Position (if applicable): N/A

Name: MATTOON, DANIEL

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: MATTOON & ASSOC, LLC. Client Name: PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA

**LOBBYING ACTIVITY**

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: PHA (one per page)

16. Specific lobbying issues:

HR 1585 & S 1547 National Defense Authorization Act - provisions related to drug pricing - HR 1038 & S 623 Access to Life Saving Medicine Act; provisions related to Follow-on Biologics HR 1956 Patient Protection and Innovative Biologic Medicines Act, provisions related to Follow-on Biologics HR 2900 Food and Drug Administration Amendments Act of 2007 - all provisions S 1082 Food and Drug Administration Revitalization Act - all provisions

17. House(s) of Congress and Federal agencies contacted:  
HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area:

Name: GOODING, REBECCA

Covered Official Position (if applicable): N/A

Name: MATTOON, DANIEL

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Signature: ON FILE Date: Aug 10, 2007

Printed Name and Title: REBECCA GOODING, PRINCIPAL -

**Information Update Page:**

**Complete ONLY where registration information has changed.**

**LOBBYIST UPDATE**

**23. Name of each previously reported individual who is NO LONGER expected to act as a lobbyist for the client**

**ISSUE UPDATE**

**24. General lobbying issues previously reported that NO LONGER pertain**

**AFFILIATED ORGANIZATIONS**

**25. Add the following organization(s)**

**26. Name of each previously reported organization that is NO LONGER affiliated with the registrant or client**

**FOREIGN ENTITIES**

**27. Add the following foreign entities**

**28. Name of each previously reported foreign entity the NO LONGER owns, OR controls, OR is affiliated with the registrant, client or affiliated organization**

Signature: ON FILE      Date: Aug 10, 2007

Printed Name and Title: -